Patent Application
20150140088
This invention relates to the chemical and pharmaceutical branches, and more specifically with obtaining new molecular entities, synthetic variants of steranes fused steroids of a general formula:
For compounds of general formula I, II, III and IV, R1, R2 and R4 represents H, hydroxyl, cetal, alcoxyl, alkanyloxyl, alkenoxyl and alkoxylcarbonyloxyl groups (preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof).
For compounds of general formula I, II, III and IV, R1, R2 and R4 also represents an amine group, preferable substituted with alkylamines, dialkylamines, alkenylamines, dialkenylamines, aminecarbonyloxyl, alkinylamines and dialkinylamines groups (preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof).
For compounds of general formula I, II, III and IV, R1, R2 and R4 also represents amide, thiol, sulphinyl, sulphonamide and sulphonyl groups, preferable substituted with alkylaryl, alkanoyloxyaryl, alkanoyloxyaryl and alkenylaryl groups (preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof).
For compounds of general formula I, II, III and IV, R1, R2 and R4 also represents an cyane, thiocyane, isothiocyane groups, preferable substituted with alkyl, acidalkyl, alkanyloxylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, arylalkinyl, arylalkylalkinyl, alkanoyloxyarylalkylalkinyl, heteroaryloxyalkinyl, heteroaryloxyalkinyl, oxoalkinyl, or cetal groups, wherein the cyanilalkinyl substituents can be substituted in turn by heteroarylalkinyl, hydroxyalkinyl, alcoxyalkinyl, aminoalkinyl and acyloaminoalkinyl groups (preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof).
For compounds of general formula I, II, III and IV, R1, R2 and R4 also represents a phosphoryl group, preferable substituted with alkylaryl, alkanyloxyaryl, alkenyloxyaryl and alkenylaryl groups (preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof).
For compounds of general formula I, II, III and IV, R3 represents an H or hydroxyl group.
For compounds of general formula I, II, III and IV, R5 represents H, hydroxyl, cetal, amine, thiol and cyane groups.
For compounds of general formula I, II, III and IV, R6 represents methyl, lipid chains derived from mono or polyunsaturated fatty acids having up to 24 carbon atoms and proteins union site groups.
For compounds of general formula III and IV, Rx represents alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof, wherein x is different from zero.
For compounds of general formula III and IV, Rx also represents alkylaryl, alkanyloxyaryl, alkenyloxyaryl and alkenylaryl groups, preferable alkyl groups having up to 8 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and all chain isomers thereof, wherein x is different from zero.
These novel compounds can serve as a basis for therapeutic drugs to treat anxiety, ischemia, epilepsy, hypertension and other cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric, and neurological disorders, as well as other disorders related to acute and chronic inflammation.
Compounds of I, II, III and IV type are obtained by tosylation of 3β-hydroxy group and hydroxylation of 6β-one group, in presence of carbonates. Oxidative reactions can employ Jones's reactive (CrO3-H2SO4), Collins's reactive (CrO3-acetone) or pyridinium chlorocromate, as oxidant agents according to Aburatani's method; or with oxoammonium-iodine salts.
Steroids were one of the first pharmacological entities denominated privileged anti-inflammatory structures. Generally, most steroid molecules act as immunosuppressive agents, through molecular mechanisms including rapid non-genomic and genomic effects. However some steroids, such as hydrocortisone, cortisone, prednisone, prednisolone, fludrocortisone, deoxycorticosterone, methylprednisolone, triamcinolone, paramethasone, betamethasone, dexamethasone, triamcinolone acetonide, acetoxyprenolone, among others, causes some toxicological effects in several organs. Therefore long-term clinical usage of those molecules induces different side effects, such as cellular metabolic disorders, osteoporosis, hypertension and gastrointestinal diseases.
In other words, the well-known neurosteroids have sedative, anesthetic and anti-convulsive affects in animals and humans. Such biological activity are due to the modulation of neuronal excitability, through the interaction between membrane receptors and ion channels, principally GABAA receptor, which acts in a bidirectional inhibitory system connected to different areas in the CNS.
Disclosed herein are new steroid compounds and compositions and their application as pharmaceuticals for the treatment of anxiety, ischemia, epilepsy, hypertension and other cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric, and neurological disorders, as well as other disorders related to acute and chronic inflammation.
After an analysis of the structure of the molecules tested and their effects on vitality of damaged PC12, as an indicator of their neuroprotective potential, the use of synthetic variants of steroids fused with spirostanes cycles for treating cerebrovascular, neurodegenerative, neuropsychiatric and neurological diseases is justified.
The novelty in this invention is obtaining a spirosteroid molecular system for potential application in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological diseases, as well as the possibility of obtaining these spirosteroid systems using a simple method of synthesis and steroid sapogenin-like diosgenin, hecogenin and solasodine as starting materials.
There are several patents describing steroids derivatives for treating CNS and inflammatory diseases. In such cases, however, no description is made of the fusion of these nucleuses or the inclusion of spirostanes cycles to form a new pharmacologic entity. Patents using different substituents of the spirosteroid nucleus, having no relation with the subject matter of our invention are listed below:
Patents U.S. Pat. No. 6,909,007, U.S. Ser. No. 186,708 and U.S. Pat. No. 5,116,829 describe the process of obtaining steroid molecules as potential anti-inflammatory entities less toxic than conventional pharmaceuticals, but use hydrogen-type substituents, alkyl and alkenyl chains, and aromatic rings of the phenyl, carboxyphenyl, acetoxyphenly, methoxycarboxyphenyl and dimethylcarboxyphenyl type. U.S. Pat. No. 5,599,807 describes the process of obtaining steroid molecules with an ester group between carboxyl group of kinoloncarboxylic acid and alcoholic hydroxyl group in position 21, with anti-bacterial and anti-inflammatory activities without long-term immunosuppression.
Patent US20030092692 describes chemical production and application of known and novels 7α-hydroxy steroid molecules on in vitro cytoprotection of neuronal cells and for treatment of acute diseases affecting CNS. However, described substituents only includes H, hydroxyl, sterified hydroxyl, alkyl, amine, alkylamine and dialkylamine groups. The patents US200330186953, US20090227551 and US201001304559 also describes the process of obtaining, and application as treatment of neurological diseases, of 3-hydroxy-7β-hydroxy and some cetonide derivatives, but their described substituents omit spirostanes cycles.
Patent US20040072806 describes only the methods, combinations and applications for treatment and prevention of neurological diseases, of natural 22R-hydroxy steroid derivatives substituted with spirost-5-en-3-ol groups.
The spirosteroid synthetic variants, the subject matter of our invention, showed some kind of action upon neuronal cells. However, the degree of the action depends on the nature of the R substituent at the 3 and 6-positions and the nature of R2 and R4 substituents.
General experimental conditions: Fusion temperatures were determined with an Electrothermal 9100 capillary hot plate equipment. IR spectrums were registered by a Philips Analytical PU 9600 FTIR spectrophotometer in KBr tablets. The NMR 1H and NMR 13C were recorded by a Brucker ACF-250 spectrometer operating at 250.13 MHz and 62.50 MHz, respectively. All those records were determined at 26° C., with CDCl3 as solvent and TMS as internal reference. Spectral assignments in NMR were developed employing the correlating spectrum (HHCOSY y HCCOSY) for some compounds, edition DEPT technique, and comparing with spectral data of compounds reported from literature.
Those compounds with 3α,5-cyclo-6-one structure, were obtained through Aburatani's method, which employs the 5-en-3β-ol system as starting material and consists in three principals stages. These experimental stages are performed in a continuous way and are the following:
The spectroscopic reported data corroborates the proposed structures. In FTIR spectrums are observed the typical bands in 1350 to 850 cm−1 zones, due to vibrations of spiroketal systems, associated to narrowing in C—C and C—O bonds. These evidences demonstrate there were not structural degradation changes in E and F rings. Moreover, the band in 880-910 cm−1 is about twice more intense than the band in 925-910 cm−1, therefore all synthesized compounds belongs to 25R series. The frequency zone 1713-1735 cm−1, corresponding to acetoxy group CH3—CO—O—, is typical for synthesized acetoxy derivatives. The band in 1360 and 1170-1175 cm−1, corresponding to asymmetric and symmetric vibrations of SO2 group (v SO2 s and as.), are characteristic for the tosyl derivative. To this grouping corresponds the band in 1588 cm−1 assignable to an aromatic v C═C.
The NMR-1H and 13C spectroscopy were informative in order to elucidate the structure of synthesized compounds. Among common significant signals are those of protons from methyl groups (CH3) 18, 19, 21 and 27, and those of protons H2-26 and H-16α. The H2-26 signal is complex and corresponds to both chemical shifts H-26α and H-26β, which practically does not vary in the series of studied compound. The axial H-26β is a triplet with δ=3.32 ppm; and its multiplicity results from a germinal quasi degenerate and vecinal axial-axial (J2≅J3=10.6 Hz) double coupling. The H-26β signal is a double doublet with δ=3.5 ppm; and its multiplicity results from a germinal coupling (J2=10.6 Hz) and vecinal equatorial-axial (J3ea=2.6 Hz). With a chemical shift of γ=4.4 ppm, the appearance of a double doublet is typical for H-16α, due to its coupling with protons 15β (equatorial), 15α and 17β (quasi-equatorials).
The signals of olefinic protons H-2 and H-3 with δ=5.5 and 5.7 ppm, respectively, are characteristics for Δ2-6-oxo steroidal compounds. The signals of 7β and 5α protons appear superpose in 2.3-2.4 ppm. In NMR-13C C-2 and C-3 signals are unshielded to δ=124.4 and 124.5 ppm, respectively, while C-4 shields to 21.7 ppm.
PC12 constitute a neuron-like cell line widely employed in several models of neurological diseases. The patophysiological mechanisms which can be simulated in those in vitro models, allows the use of PC12 cells in evaluation of therapeutic candidates.
The synthetic spirosteroids series (10 μM of each molecule) was evaluated on PC12 cells exposed to L-glutamate (20 mM) for 24 h. Previously, those cells were routinely cultivated in RPMI 1640 medium, supplemented with equine serum (10%) and fetal bovine serum (5%) in a 37° C. and 5% CO2 atmosphere. In the beginning of the experiment, cells were seeded in 96-well microplates at a cellular density of 150,000 cells/mL. After 24 h of exposition to glutamatergic damage and spirosteroids treatment, cellular vitality was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), which is metabolized by mitochondrial deshydrogenases in living cells. Our results (Table 2) demonstrate an anti-glutamatergic and neuroprotector effect of several spirosteroids molecules (S) related to some structural features. Specifically, between the most active molecules was 2α,3α-dyhydroxy-(25R)-spirostan-6-one and 3,6-dione-(25R)-spirostan. All molecules of the synthetic spirosteroids series were non cytotoxic at the concentration employed for the in vitro anti-glutamatergic assay (data no shown).
| Number | Date | Country | Kind |
|---|---|---|---|
| P/2011/0244 | Dec 2011 | CU | national |
This application is a 371 U.S. National Phase Patent Application which claims priority to PCT Patent Application No. PCT/CU2012/000008, filed Dec. 27, 2012 and Cuba Patent Application CU/P/2011/0244, filed Dec. 27, 2011 and incorporates the above-referenced applications in their entireties by reference thereto.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CU2012/000008 | 12/27/2012 | WO | 00 |
